In the current study, our goals were to distinguish the roles of mPGES-1 from those of COX-2 in tumor immunity and to directly test the potential of mPGES-1 inhibitors as an adjuvant to immune-based therapies for melanoma in a preclinical mouse model. This evidence concerns the gene PTGS2 and neoplasm.